{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-008076","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.971267+00:00","generated_at":"2026-06-19T05:43:16.209110+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eterna enters exclusive license with Factor for patents; prior deal terminated","bullets":["Exclusive worldwide license under Factor's patents for human uses; term ends Nov 22, 2027, auto-renewed 2.5 years if Eterna receives $100M in sublicense fees.","Eterna pays Factor 20% of sublicense fees before expiration, 30% during renewal; CEO Matthew Angel is co-founder/CEO of Factor's parent (related party).","Prior license agreement (April 2021, amended Nov 2022) terminated and superseded by this new agreement on Feb 20, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-008076","json":"https://secwatch.observer/filing/0001140361-23-008076.json","markdown":"https://secwatch.observer/filing/0001140361-23-008076.md","text":"https://secwatch.observer/filing/0001140361-23-008076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/brhc10048628_form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T05:43:16.209110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8777b1b19388a873323135c2324322724aab3f88","claim":"Ernexa Therapeutics Inc. entered into Exclusive License Agreement with Factor Bioscience Limited valued at 20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub (effective 2023-02-20).","evidence_excerpt":"On February 20, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into an exclusive license agreement (the “ Exclusive License Agreement ”) with Factor Bioscience Limited (“ Factor ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Factor Bioscience Limited"},{"label":"Value","value":"20% of Sublicense Fees before Expiration Date, 30% during Renewal Term; at least $100 million in sub"},{"label":"Effective","value":"2023-02-20"}],"fact_type":"material_agreement"},{"claim_id":"dccb9625b16692620c272f029b78f7f644281f09","claim":"Ernexa Therapeutics Inc. terminated Amended Factor License Agreement with Factor valued at Terminated and superseded by Exclusive License Agreement (effective 2023-02-20).","evidence_excerpt":"Effective on February 20, 2023, the Exclusive License Agreement terminated and superseded the Amended Factor License Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Factor"},{"label":"Value","value":"Terminated and superseded by Exclusive License Agreement"},{"label":"Effective","value":"2023-02-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}